Purification of CD4+ T Cells for Adoptive Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 374-383

  Klyuchnikov, Evgeny ^a   Sputtek, Andreas ^a   Slesarchuk, Olga ^a,b   Lioznov, Michael ^a   Stübig, Thomas ^a   Bacher, Ulrike ^a   Amtsfeld, Gitta ^a   Merle, Edeltraut ^a   Reckhaus, Marie Luise ^a   Fehse, Boris ^a   Wolschke, Christine ^a   Adjallé, Raissa ^a   Ayuk, Francis ^a   Zander, Axel ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Adoptive immunotherapy; Allogeneic hematopoietic stem cell transplantation (HSCT); CD4+ cell selection; Graft versus host disease (GVHD)

Indexed keywords

ACICLOVIR; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; ETOPOSIDE; FLUDARABINE; FOSCARNET SODIUM; IMATINIB; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; TREOSULFAN;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL SELECTION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; LEUKAPHERESIS; MALE; MEDICAL INSTRUMENTATION; MULTIPLE MYELOMA; PURIFICATION; REFRACTORY PERIOD; SURVIVAL; T CELL DEPLETION; TREATMENT RESPONSE;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OPPORTUNISTIC INFECTIONS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 79551689326     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.003     Document Type: Article

References (54)

1. Drobyski W.R., Ash R.C., Casper J.T., et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994, 83:1980-1987.
2. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
3. Sehn L.H., Alyea E.P., Weller E., et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol 1999, 17:561-568.
4. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
5. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
6. Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000, 95:67-71.
7. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268.
8. Dey B.R., McAfee S., Colby C., et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003, 9:320-329.
9. Marks D.I., Lush R., Cavenagh J., et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002, 100:3108-3114.
10. Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004, 103:1548-1556.
11. Mohty M., Bagattini S., Chabannon C., et al. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol 2004, 32:1097-1102.
12. Alyea E.P., Soiffer R.J., Canning C., et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998, 91:3671-3680.
13. Giralt S., Hester J., Huh Y., et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995, 86:4337-4343.
14. Meyer R.G., Britten C.M., Wehler D., et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007, 109:374-382.
15. Alyea E., Weller E., Schlossman R., et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001, 98:934-939.
16. Soiffer R.J., Alyea E.P., Hochberg E., et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002, 8:625-632.
17. Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23:3-9.
18. Draube A., Pfister R., Vockerodt M., et al. Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Ann Hematol 2001, 80:83-89.
19. Tefferi A., Barosi G., Mesa R.A., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108:1497-1503.
20. Alizadeh M., Bernard M., Danic B., et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002, 99:4618-4625.
21. Fehse B., Chukhlovin A., Kuhlcke K., et al. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001, 10:419-425.
22. Kroger N., Badbaran A., Holler E., et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109:1316-1321.
23. Kroger N., Alchalby H., Klyuchnikov E., et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009, 113:1866-1868.
24. Cheson B.D., Bennett J.M., Kantarjian H., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
25. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
26. Bang K., Lund M., Wu K., et al. CD4+ CD8+ (thymocyte-like) T lymphocytes present in blood and skin from patients with atopic dermatitis suggest immune dysregulation. Br J Dermatol 2001, 144:1140-1147.
27. Paliard X., Malefijt R.W., de Vries J.E., et al. Interleukin-4 mediates CD8 induction on human CD4+ T-cell clones. Nature 1988, 335:642-644.
28. Parel Y., Chizzolini C. CD4+ CD8+ double positive (DP) T cells in health and disease. Autoimmun Rev 2004, 3:215-220.
29. Sullivan Y.B., Landay A.L., Zack J.A., et al. Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells. Immunology 2001, 103:270-280.
30. Berrih S., Gaud C., Bach M.A., et al. Evaluation of T cell subsets in myasthenia gravis using anti-T cell monoclonal antibodies. Clin Exp Immunol 1981, 45:1-8.
31. Mizutani H., Katagiri S., Uejima K., et al. T-cell abnormalities in patients with idiopathic thrombocytopenic purpura: the presence of OKT4+8+ cells. Scand J Haematol 1985, 35:233-239.
32. Munschauer F.E., Stewart C., Jacobs L., et al. Circulating CD3+ CD4+ CD8+ T lymphocytes in multiple sclerosis. J Clin Immunol 1993, 13:113-118.
33. Ortolani C., Forti E., Radin E., et al. Cytofluorimetric identification of two populations of double positive (CD4+, CD8+) T lymphocytes in human peripheral blood. Biochem Biophys Res Commun 1993, 191:601-609.
34. Weiss L., Roux A., Garcia S., et al. Persistent expansion, in a human immunodeficiency virus-infected person, of V beta-restricted CD4+CD8+ T lymphocytes that express cytotoxicity-associated molecules and are committed to produce interferon-gamma and tumor necrosis factor-alpha. J Infect Dis 1998, 178:1158-1162.
35. Bagot M., Echchakir H., Mami-Chouaib F., et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 1998, 91:4331-4341.
36. Deol A., Lum L.G. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010.
37. Tomblyn M., Lazarus H.M. Donor lymphocyte infusions: the long and winding road: how should it be traveled?. Bone Marrow Transplant 2008, 42:569-579.
38. Chiorean E.G., DeFor T.E., Weisdorf D.J., et al. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004, 10:171-177.
39. Huff C.A., Fuchs E.J., Smith B.D., et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006, 12:414-421.
40. Michallet A.S., Nicolini F., Furst S., et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant 2005, 35:601-608.
41. Raiola A.M., van Lint M.T., Valbonesi M., et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003, 31:687-693.
42. Schattenberg A., Schaap N., van de Wiel-Van Kemenade, et al. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Leuk Lymphoma 1999, 32:317-325.
43. Verdonck L.F., Petersen E.J., Lokhorst H.M., et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998, 22:1057-1063.
44. Griffioen M., van der Meijden E.D., Slager E.H., et al. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proc Natl Acad Sci USA 2008, 105:3837-3842.
45. Zorn E., Wang K.S., Hochberg E.P., et al. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002, 8:2052-2060.
46. Zorn E. CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. Semin Cancer Biol 2006, 16:150-159.
47. Kernan N.A., Collins N.H., Juliano L., et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986, 68:770-773.
48. Orti G., Lowdell M., Fielding A., et al. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation. Transplantation 2009, 88:1312-1318.
49. Lai Y.P., Lin C.C., Liao W.J., et al. CD4+ T cell-derived IL-2 signals during early priming advances primary CD8+ T cell responses. PLoS One 2009, 4:e7766.
50. Shimoni A., Gajewski J.A., Donato M., et al. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2001, 7:568-575.
51. Matte-Martone C., Liu J., Jain D., et al. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Blood 2008, 111:3884-3892.
52. Merad M., Hoffmann P., Ranheim E., et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004, 10:510-517.
53. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8:575-581.
54. Ratzinger G., Reagan J.L., Heller G., et al. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003, 101:1422-1429.